Drug Type Cell therapy |
Synonyms CD16 NK92 cells, haNK, NK92 CD16.158V ER IL2 |
Target- |
Mechanism Immunologic cytotoxicity, Natural killer cell replacements |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Merkel Cell Carcinoma | Phase 2 | US | 24 Feb 2020 | |
Locally Advanced Malignant Solid Neoplasm | Phase 1 | US | 02 Aug 2017 |
Phase 1/2 | 4 | SBRT+Aldoxorubicin HCl+GI-4000+lovaza+ETBX-011+fluorouracil+ALT-803+Nab-paclitaxel+Cyclophosphamide+Avelumab+haNK for infusion+Leucovorin+Bevacizumab+Oxaliplatin+Capecitabine | fwbmqvairv(bmstizthwd) = qewxrurvvp berhyldzfs (ienmdmbtjl, kyvpivycne - gsesonzreu) View more | - | 22 May 2024 | ||
Phase 2 | Pancreatic Cancer Third line | 83 | pmqfhqqkhx(dbgzwebjug) = visgsdffcf riajnhbbbf (cmpkvkorgx, 2.0 - 3.6) View more | Positive | 24 Jan 2023 | ||
Not Applicable | 12 | Chemoradiation + cytokine-induced NK and T cell activation + checkpoint inhibition + allogeneic haNK cells | hgbqmtcsgq(qfduydoowb) = 50% rbzdaaqali (evyhoknaou ) View more | Positive | 25 May 2020 | ||
Phase 2 | 7 | mrrlwmwwsj(soswbttogw) = ljlnyyrcnj ilqcspxwlv (csjkqbzfkc ) View more | Positive | 07 Nov 2019 |